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 Influenza viruses are pathogens that can cause major pandemics in the human 
population, such as the Spanish Flu outbreak in 1918-1919, which caused about 50 
million deaths worldwide.  As the virus frequently mutates, vaccines and anti-viral drugs 
can be rendered ineffective over time.  As new influenza viruses emerge, new anti-viral 
therapies are essential. The goal of this study was to identify novel means to inhibit 
influenza viral replication, by targeting the activity of the Vacuolar ATPase (V-ATPase) 
proton pump. The V-ATPase pump is a multi-molecular proton pump that couples ATP 
hydrolysis to proton transport, thus regulating the pH of intracellular compartments. This 
activity is also used by the influenza virus to induce viral uncoating during infection. In 
this study, I examined how changes in glucose concentrations affect V-ATPase pump 
activity and influenza replication. Through immunostaining of mammalian cells, I 
observed that higher levels of glucose caused specific localization of the V-ATPase 
proton pumps within the cell, thus triggering pump activity.  Western blot analysis of two 
V-ATPase proton pump proteins showed that protein synthesis of the pump was not 
affected by increasing the amount of glucose. Based on these results, I examined the 
effect of increasing glucose levels upon influenza infection. I found that higher amounts 
of glucose yielded higher influenza infection levels. Additionally, viral infection was 
significantly reduced after inhibition of glycolysis with 2-deoxyglucose and 3-
bromopyruvate. Lastly, I bypassed the need for glycolysis via addition of extracellular 
ATP. The V-ATPase pump activity was restored after glycolytic inhibition with ATP 
treatment as indicated by an increased number of virally infected cells. Taken together, I 
propose that inhibiting influenza replication in mammalian cell cultures by altering 
activity of the V-ATPase proton pump via inhibition of glycolysis could be a potential 
new approach for the treatment of influenza infection.  
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CHAPTER I 
INTRODUCTION 
Influenza Virus 
 Influenza viruses are respiratory viruses, and members of the orthomyxovirus 
family. Influenza viruses are single-stranded negative RNA viruses with eight RNA 
molecules found within an envelope. Four of the RNA segments code for specific 
ribonucleoproteins (RNPs): the PB1, PB2, PA polymerase proteins and the nucleoprotein 
(NP). The other four RNA segments code for essential proteins: the glycoproteins 
hemagglutinin (HA) and neuraminidase (NA), the ion channel or integral protein (M2), 
and the matrix protein (M1) which is thought to be required during viral assembly and 
recruitment at the apical membrane (Palese and Shaw 2007). The nuclear export protein 
(NEP) and the nonstructural protein 2 (NS2) are suggested to play a role in RNP export 
during budding (Figure 1) (Palese and Shaw 2007). It is important to note that some of 
the RNA segments code for two proteins. The lipid envelope of the virus is derived from 
the host plasma membrane and harbors the two glycoproteins HA and NA and the ion 
channel M2 (Palese and Shaw 2007). Three types of influenza viruses which are 
antigenically different have been identified: influenza A, B, and C.
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Figure 1. Schematic representation of influenza virus. The RNA polymerases, the 
nucleoprotein (NP) and all RNA segments are located in the interior of the envelope. 
(Modified from Palese and Shaw 2007). 
 
Influenza can infect a wide range of organisms from mammals to birds, causing major 
pandemics as well as endemics and epidemics. One significant outbreak was identified in 
1918 and is commonly referred to as the “Spanish flu”. This led to at least 50 million 
deaths worldwide in 1918-1919 (Betakova 2007). Other pandemics were identified in 
1957, 1968, 1977 and 2009 (Palese and Shaw 2007, CDC), mostly caused by an influenza 
type A virus.  
 Influenza viruses lead to severe infection of the epithelial cells of the upper and 
lower respiratory tract. Infection by the influenza virus is caused by the transport of viral 
genome into the nucleus of the host cell where transcription and replication of the viral 
genome take place (Palese and Shaw 2007, Betakova 2007) (Figure 2).  
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Figure 2. Influenza replication. After endocytosis by binding to sialic acid (receptor), the viral genome is released into 
the cytoplasm and transported into the nucleus. Replication and transcription of the viral genome take place in the 
nucleus. The mRNA is transported to the cytoplasm where translation of viral proteins takes place. Polymerases, NP, 
and NS2 are transported back into the nucleus to further aid viral replication. Viral assembly occurs at the plasma 
membrane. HA, NA, and M2 glycoproteins are sent to the plasma membrane via the Golgi apparatus. (Modified from 
Influenza Report 2006). 
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Entry of the virus into the cytoplasm is initiated by binding of the HA glycoprotein to its 
receptor sialic acid on the cell surface. Following attachment, the virus is transported into 
the cytoplasm in an endocytic vesicle. The M2 ion channel plays a significant role in viral 
uncoating. In fact, the M2 protein, which is activated by the acidic pH of the vesicle 
(Pinto and Lamb 2006, Betakova 2007), transports protons from the vesicle into the 
interior of the virion. M2 activity helps lower the pH inside the virion, allowing viral 
uncoating through dissociation of M1 from the viral genome (Betakova 2007). In 
addition, the decrease in pH also helps release the viral genome by promoting a 
conformational change in the HA glycoprotein which triggers the fusion of the 
endosomal membrane with that of the viral membrane (Palese and Shaw 2007). 
 Following replication using its own polymerases (within the nucleus), the virus is 
assembled at the apical membrane of the cell where the new viral particles bud and 
release into the cytoplasm (Palese and Shaw 2007). Release of viral particles is initiated 
by NA activity that cleaves sialic acid from the cell surface. This activity allows 
dissociation of the virus from the cell (Betakova 2007). 
Influenza viruses can undergo reassortment, where different RNA segments are 
selected from cells infected with multiple influenza viruses (Palese and Shaw 2007). 
Reassortment leads to the emergence of new potentially infectious strains. In fact, the 
1957 and 1968 pandemics emerged as a result of the reassortment of viral genomes 
(Palese and Shaw 2007). 
 Antivirals drugs have been used for the treatment of influenza infection. 
Amantadine and rimantadine are two inhibitors of the M2 protein that are mostly 
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effective in the treatment of influenza type A (Palese and Shaw2007). These drugs act by 
blocking M2-mediated proton transport into the virion. Zanamivir and oseltamivir are 
effective on both influenza type A and B (Palese and Shaw 2007). They act by inhibiting 
the NA glycoprotein.  However, the virus develops a rapid resistance to the drugs which 
limit their effectiveness (Betakova 2007). In addition to the drug treatment, influenza 
vaccines have been used. Unfortunately, the vaccines may not be fully effective since 
they are based on the previous influenza strains which may not emerge at a given time.  
The M2 ion channel is essential for viral uncoating through acidification of the interior of 
the viron. However, one additional protein complex, the Vacuolar H+ ATPase proton 
pump located within endosomal membranes, was also identified to be involved in 
influenza viral entry by maintaining the acidic pH necessary for viral release (Guinea et 
al 1995, Jefferies et al 2008). 
 
Vacuolar ATPase Proton Pump 
 Vacuolar type H+ ATPases (V-ATPases) are multisubunit proton pumps that 
couple ATP hydrolysis to the transport of protons from the cytoplasm into the lumen of 
endosomes or organelles. This activity leads to the acidification of intracellular 
compartments, necessary for multiple cellular processes (Jefferies et al 2008). V-ATPase 
pumps share similar function and structure with the F-ATPase pumps found in the plasma 
membrane of bacteria (Nishi & Forgac 2002). 
 The V-ATPase pumps were first identified in lysosomal compartments and the 
central vacuole of the yeast Saccharomyces cerevisiae and in plants (Kakinuma et al. 
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1981), necessary for macromolecule degradation. V-ATPase pumps are now known to be 
ubiquitously found in the endomembrane system of eukaryotic cells including 
mammalian cells. The V-ATPase pumps were also found to be present in the collecting 
duct of mammalian kidney (Wagner et al. 2004), osteoclasts (Chatteriee et al. 1992), 
sperm, macrophages, and insect gastrointestinal epithelia (Harvey, W.R 1992 and Klein 
1992). Therefore, V-ATPase pumps exist on the plasma membranes of specialized cells 
and within many organelles.  
 V-ATPases are composed of a peripheral V₁ domain (400-600 kDa) and an 
integral V0 subcomplex (150-350 kDa) (Figure 3). The V₁ subcomplex contains eight 
subunits, two of which interact with ATP and provide the energy necessary for active 
transport of protons against a concentration gradient. Subunits of the V₁ domain are 
represented by the capital letters A, B, C, D, E, F, G, and H. The V0 subcomplex which 
consists of six subunits carries proton transport into the lumen. Subunits of the V0 
domain are identified by the lower case letters a, c, d and e, with subunit c consisting of 
different isoforms, c’ and c” (Jefferies et al. 2008). The V₁ and V0 domains form two ring 
structures that function through a rotary mechanism (Hirata et al. 2003). ATP binding to 
the catalytic sites on the V₁ domain, specifically on the A and B subunits, leads to 
conformational changes in the A subunit which drives rotation of the rotor comprised of 
subunits D, F and d and the proteolipid c-ring (Jefferies et al. 2008 and Beyenbach et al. 
2006). This activity drives proton translocation from the cytoplasm into the lumen 
through passage via the V0 a subunit (Figure 3).  
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           Figure 3. V-ATPase pump structure (Modified from Sze, 2002 and Kane, 2006). 
 
 
V-ATPase activity is regulated through disassembly of the V₁ and V0 domains. 
This process helps regulate the pH levels of organelles inside the cell (Bond and Forgac 
2008). One of the mechanisms that regulate the V-ATPase activity is glucose depletion 
(Kane 2006). A V-ATPase dissociation mechanism was first observed in yeast and 
Manduca sexta (Kane, 2006). It has also been shown to take place in mammals and 
insects (Xu and Forgac 2001). During disassembly, the C subunit of the V1 domain is 
released, which suggests its role in the pump assembly and disassembly (Beyenbach and 
Wieczoreck 2005, Jefferies et al 2008). V-ATPase assembly and disassembly induced by 
glucose levels is independent of the main glucose repression/depression pathway or Ras-
cAMP pathway as well as other signal transduction pathways (Parra & Kane 1998). In 
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fact, glycolysis has an indirect effect on V-ATPase activity. Pump disassembly can also 
result from a reduction in ATP levels (Para and Kane 1998).  
 
 
Glycolysis and Vacuolar ATPase  
 The Embden - Myerhof pathway, commonly referred to as glycolysis, is the 
process by which glucose metabolism occurs to generate a net gain of two ATP, two 
molecules of NADH+ and two molecules of pyruvate at the end of glycolysis (Pelicano et 
al. 2006). Glycolysis takes place in two major phases. The primary phase involves the 
combustion of two ATP to convert glucose into fructose 1-6-bisphosphate. The second 
stage of glycolysis converts fructose 1-6-bisphosphate into molecules of glyceraldehyde -
3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) that is further oxidized into 
lactate or pyruvate. DHAP is converted back into GAP before further oxidation. Specific 
enzymes catalyze each stage of glucose metabolism (Figure 4) (Pelicano et al. 2006). 
 Glycolysis has an indirect effect on V-ATPase activity; however there is a lack of 
understanding on how the energy from ATP hydrolysis is provided to the V-ATPase 
pumps needed for proton transport into the lumen (Lu et al. 2004).  Studies on yeast and 
mammals indicate a direct physical interaction between V-ATPases and aldolase, one of 
the glycolytic enzymes that converts fructose-6-phosphate into GAP (Lu et al. 2001).  
There is an increase in physical interaction between aldolase and the a, B and E subunits 
of V-ATPases pumps when glucose is present (Lu et al. 2004). Furthermore, disassembly 
and reduced levels of V-ATPase activity were observed in mutant aldolase yeast cells, 
and normal pump assembly and activity was restored after introduction of the wild–type 
9 
 
aldolase gene into the mutant cells (Lu et al. 2004). These findings provide evidence that 
the glycolytic enzyme aldolase mediates V-ATPase assembly and activity (Lu et al. 
2004). V-ATPase and aldolase physically interact, and in human kidney cells the rate 
limiting enzyme of glycolytic pathway, phosphofructose kinase 1 (PFK-1) interacts with 
the a-subunit of the pump via the C-terminus region of the subunit (Su et al. 2003). A 
study conducted in our lab also identified glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH) as a modifier of M2 ion channel activity (Unplublished). Thus alterations in 
glycolysis may affect V-ATPase activity, and this in turn may affect M2 activity, and 
therefore alter influenza replication. 
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Project Overview  
 The primary function of the V-ATPase proton pump is to acidify intracellular 
compartments. The lowered endosomal pH sustained by V-ATPase pumps also plays a 
crucial role in influenza viral infection. Influenza virus enters the host cell through 
endocytosis and is contained within a vesicle. The viral genome is released in response to 
the low pH provided by the V-ATPase pumps found in the vesicle, via an increase in M2 
activity.  The goal of this study was to address the implication of V-ATPase pumps 
activity with respect to glucose metabolism, and how this process affects influenza viral 
infection of mammalian cells.  
 
Specific Aims 
1. Analyze the effect of glucose at low and high concentrations on V-ATPase pump 
localization/assembly. 
2.  Investigate if influenza infection is dependent upon glucose levels. 
3. Determine if changes in glucose concentrations affect the protein expression 
levels of the V-ATPase pump components. 
4. Determine the effect of glucose metabolism in influenza viral infection. 
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CHAPTER II 
MATERIALS AND METHODS 
Reagents 
 2-deoxyglucose (2-DG) (Product # D8375), 3-bromopyruvate (3-BrPa) (Product # 
16490), Lonidamine (LND) (Product # L4900), 6-aminocicotinamide (6-AN) (Product # 
A68203) and Adenosine 5’trisphosphate disodium salt hydrate (ATP) (Product # A2383) 
were purchased from Sigma. Cells and influenza A H1N1 virus (A/PR/8/34) (Product # 
VR-1469) were purchased from ATCC. 
 
 
Cell Culture 
 
 Human cervical cancer (HeLa) and Madin-Darby Canine Kidney (MDCK) cells 
were maintained in a high glucose Dulbecco’s Modified Eagles Medium (DMEM) from 
Thermo Scientific supplemented with 10% Fetal Bovine Serum (FBS) as well as 
penicillin/streptomycin (500µl) and an antifungal agent (500µl). Cells were maintained at 
37ºC in an air jacketed incubator with 5% CO2. 
 
Infection Medium 
 Infection medium was prepared using influenza A H1N1 virus (A/PR/8/34) at a 
Multiplicity of Infection (MOI) of 1, contained in low glucose DMEM from Thermo 
Scientific along with 1μg/ml trypsin, 0.125% BSA, and 1% HEPES. No serum, penicillin 
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nor antifungal agent were added.  Cells were treated accordingly for 24 hr with 2ml of the 
infection medium containing influenza A virus.   
 
Immunostaining for V1A1 and V1B1/2   
 Confluent HeLa cells were plated (8 x 104 cells/ml) on coverslips in 35 mm cell 
culture dishes each containing 1mg/ml (low) for our control treatment and 6mg/ml (high) 
glucose (total volume of 2ml of medium was added to each plate). Twenty-four hour 
later, 1µl of Fu-gene (Transfection reagent) (Promega) was added to each plate. Cells 
were washed with 1x phosphate buffered saline (PBS) and a fresh glucose-containing 
media was added for another 24 hr. Coverslips were transferred to a 24 well plate, rinsed 
in  1xPBS and fixed in 4% paraformaldehyde at room temperature for 15min. Cells were 
incubated in incubation mix (1xPBS, 0.3% BSA, 0.1%Triton X, 5% goat serum) for 10 
min. Cells were incubated for an additional 1hr at 37ºC with V1A1 (Product # sc-20943) 
or V1B1/2 (Product # sc-28801) (Santa Cruz) primary antibody, diluted 1:200 in 
incubation mix. Cells were washed 4 times with 1xPBS on a rotating platform followed 
by incubation for another 40 minutes at 37ºC with a Donkey-Anti-Rabbit -CY3 (Jackson 
ImmunoResearch Laboratories) secondary antibody diluted 1:200. Cells were washed 4 
times as previously described. Hoescht stain was diluted 1:2000 in 1xPBS for the last 
wash. Coverslips were mounted in Fluorescent Mounting Medium (DakoCytomation). 
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 Immunostaining for HA 
 Confluent MDCK cells were harvested then plated at (8 x 104 cells/ml) in 2ml of 
low glucose and allowed to grow for 24 hr in 35mm cell culture dishes with coverslips. 
Cells were plated at 1(control), 2, 3, 4, 5 or 6mg/ml of. After 24 hr, cells were washed 
with 1x PBS, infected with influenza A H1N1 and new glucose was added. Cells were 
infected for 24hr. Immunostaining was conducted as previously. An anti -HA primary 
antibody (Product # sc-52025) (Santa Cruz) with a dilution of 1:200 was used. A Goat-
Anti-Rabbit -CY3 (Jackson ImmunoResearch Laboratories) secondary antibody was 
diluted 1:400. 
 
Western Blot for V1A1 and V1B1/2 
 HeLa cells were plated (8 x 104 cells/ml) in 2 ml media containing at 1(control), 
2, 3, 4, 5 or 6mg/ml of glucose. Twenty-four hour later, 1μl of Fu-gene (Promega) was 
added. Cells were washed with 1x PBS and a fresh glucose-containing media was added 
for another 24 hr. Cells were suspended in 1xPBS and the pellets were lysed in 8M urea. 
Cells were mixed with equal volume of 2x protein loading dye. Western blotting was 
performed to separate the protein on a 10% SDS- polyacrylamide electrophoresis gel 
using a Bio-Rad Mini-Protean gel apparatus. Gel was run at 200 volts for 30min in 1x 
running buffer. The proteins were transferred to a nitrocellulose membrane in a 1x 
electroblotting buffer. The blot was then blocked in a 1xPBS, 0.1% Tween 20 (Fisher 
Scientific) and 5% bovine serum albumin (BSA) (Fisher Scientific) solution. The 
membrane was incubated in a 1:2000 dilution of anti- V1A1 or V1B1/2 (Santa Cruz) 
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primary antibody for 1 hr at room temperature or overnight at 4 ºC, and washed with 
1xPBS, 0.1% Tween 20. The membrane was incubated with GAM-HRP (Goat-Anti-
Mouse-Horseradish Peroxidase) secondary antibody from Jackson ImmunoResearch 
Laboratories, diluted 1:10,000 in blocking solution with gentle rocking at room 
temperature for 30-60 min. The membrane was washed, and bound antibody visualized 
using SuperSignal (Thermo Scientific Pierce).  BioRad gel documentation was used to 
acquire image chemilumeniscence and bands were quantified using Quantity 1 software.   
 
 
Immunostaining for HA after 2-DG, 3-BrPa, LND and 6-AN Treatment  
 MDCK cells were plated in 4.5mg/ml of glucose (DMEM) from Thermo 
Scientific. Cells were treated 24 hr later with 2-DG (0, 0.25, 2, 5mM), 3-BrPa (0, 30, 300, 
600µM) or LND (0, 6, 62.5, 200µM,) (concentrations were established from Hulleman E. 
et al. (2008)), or 6-AN (0, 30, 140, 250µM) (concentrations established from Budihardjo 
I. et al. (1998)). Cells were infected with influenza A H1N1 for 24 hr following treatment 
with the drugs.  24 hr post infection, cells were washed with 1xPBS and new medium 
was added without the drugs. Immunostaining was conducted following the same 
procedure as immunostaining for V1A1 and V1B1/2, instead using an anti-HA primary 
antibody diluted 1:200 and a Goat-Anti-Mouse-CY3 secondary antibody diluted 1:400.  
 
Immunostaining for HA after ATP Treatment 
 MDCK cells were plated in 4.5mg/ml glucose (DMEM) from Thermo Scientific. 
Cells were treated 24 hr later with 2-DG (5mM). Cells were subsequently treated with 
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ATP (50, 100µM) (concentrations established from Probst I. et al. (1989)), along with 
influenza A H1N1. ATP treatment and influenza infection was conducted for 24hr. Cells 
were fixed and stained with an anti-HA primary antibody and a Goat-Anti-Mouse-CY3 
secondary antibody as previously described. 
 
Data Analysis 
 Images of immunostained cells were captured on Olympus Fluoview FV 500/IX 
81confocal microscope. Bound antibodies for Western Blot analysis were viewed using a 
BioRad imager and quantified using Quantity 1 software. Data were statistically analyzed 
using the student T-test. 
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CHAPTER III 
RESULTS 
The effect of glucose at low and high concentrations on V-ATPase pump 
localization/assembly   
 V-ATPase pump activity is downregulated by glucose depletion through 
disassembly of the peripheral V1 and the integral V0 domain in yeast Saccharomyces 
cerevisiae cells (Para and Kane 1995).  Additionally, pump assembly is modulated by the 
relative concentration of extracellular glucose in yeast (Kane 1995). I further analyzed 
pump assembly at low and high glucose concentrations in mammalian cells to visualize 
the pump’s localization and assembly within mammalian cells. To examine the V-
ATPase pump’s localization/assembly, HeLa cells lines were grown at 1mg/ml (low) or 
6mg/ml (high) glucose.  Cells were then immunostained with anti- V1A1 and V1B1/2  
primary antibodies and visualized using confocal microscopy. Images of cells showing 
the pumps localization/assembly are shown in Figure 5.  The use of both anti-V1A1 and 
V1B1/2 primary antibodies allowed me to monitor two of the pump proteins. 
Pump assembly was assed base on their localization within intracellular compartments. 
The pumps were mostly diffused within the cells at 1mg/ml (low) glucose (Figure 5A, C) 
using both anti- V1A1 and V1B1/2 primary antibodies, thus indicating a lower pump 
assembly. These results also indicate that the pumps are inactive as the V1 domain 
remains detached from the V0 domain.  Pumps were specifically localized at 6mg/ml 
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high) glucose (Figure 5 B, D). These results indicate that the pumps are assembled and 
active when glucose levels are high.
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Figure 5.V-ATPase pump localization/assembly at low and high glucose concentrations. A, B, confocal imaging at 400x 
of V-ATPase pumps assembly/ localization at 1mg/ml and 6mg/ml of glucose in HeLa cells incubated with V1A1  primary 
antibody. C, D, images at 200x of the pumps assembly/localization at 1mg/ml and 6mg/ml of glucose incubated with V1B1/2  
primary antibody. Arrows indicate the V-ATPase pumps localization in a single cell; the pumps are represented with CY3 
staining (red fluorescence).  
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Influenza viral infection is altered in response to changes in glucose concentration  
 Increasing extracellular glucose concentrations induces different levels of V-
ATPase pump assembly in yeast (Kane 1995). We observed the same effect in HeLa cells 
with an increase in pump assembly at 6mg/ml glucose. To determine if this increased 
activity of the V-ATPase (which I determined to be specifically localized within 
intracellular compartments indicating higher activity) present with high glucose also 
leads to increased influenza replication, I examined influenza viral infection in MDCK 
cells grown at varying glucose concentrations (1, 2, 3, 4, and 6mg/ml) subsequently 
infected with influenza A H1N1. MDCK cells were used as they support the effective 
propagation and replication of many influenza type A and B viruses. Additionally, HeLa 
cells that were previously used could not be infected by influenza and my V1A1 and 
V1B1/2 primary antibodies detect proteins only in human cells lines. Cells were 
immunostained with an anti-HA antibody to identify virally infected cells. Images were 
taken with a confocal microscope.  Intensity of HA glycoprotein was visualized within 
cells. Positively infected cells were determined based on HA staining (CY3 red stains) 
specific to a cells (Figure 6). Higher intensity (staining) of HA glycoprotein within 
infected cells was observed at 4 and 6mg/ml (Figure 6 D, E) compared to 1, 2, and 3 
mg/ml of glucose (Figure 6 A, B, C). Additionally, the percentage of infected cells was 
determined at each relative glucose level and increased as glucose concentration 
increased (Figure 7). The overall result from Figure 7 suggests that an increase in viral 
infection is associated with an increase in V-ATPase pumps activity/assembly when 
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extracellular glucose concentration is high.  P-value = 0.028 when comparing viral 
infection at 1mg/ml and 6mg/ml glucose. 
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Figure 6. Increasing amounts of glucose increase influenza viral infection of MDCK cells. MDCK cells were infected with 
influenza A H1N1 for 24 hr. Cells were subsequently fixed and stained with anti-HA-antibody for the detection of viral 
particles.  Blue stains represent the DNA of a single cell (DAPI) and CY3 (red staining) represent anti -HA antibody staining 
within infected cells. Confocal imaging was performed at 400x. 
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Figure 7. Graphical representation of the percentage of infected cells. Graph 
representing the percentage of infected cells at relative glucose levels. Percentage of 
infection increased as glucose levels increased. 1mg/ml (n=23), 2mg/ml (n=11), 
3mg/ml (n=27), 4mg/ml (n=14), and 6mg/ml (n=12). Note: Numbers were provided as 
the percentage of infected cells in relation to the total number of cells per confocal 
image. * indicates a P-value ≤ 0.05.  
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Increased glucose does not increase pump protein expression levels 
 To determine whether the increased pump localization that I saw with increased 
glucose was due to an increase in pump protein synthesis, I examined pump protein 
levels at varying glucose concentrations. HeLa cells were grown at 1, 2, 3, 4, and 6 
mg/ml glucose, and the cellular proteins were separated by SDS-PAGE gel. HeLa were 
use since my V1A1 and V1B1/2 primary antibodies detect proteins only in human cell 
lines. Proteins were transferred to a nitrocellulose membrane and the protein levels were 
determined by western blot analysis using anti- V1A1 and V1B1/2 primary antibodies 
(Figure 8 A and B). As indicated in Figure 8 A and B, the protein of the 2 protein 
subunits did not increase with increased glucose, suggesting that increased protein 
localization was due to assembly, not additional protein synthesis. 
 The protein bands from varying glucose concentrations analyzed with V1A1 
primary antibody were quantified with ChemiDoc software (Figure 9). With the results 
obtained, it is clear that there is not an increase of V-ATPase protein levels as I increased 
the glucose concentration.  
 
 
 
 
 
1mg/ml 
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Figure 8. V-ATPase protein synthesis is not affected at varying glucose 
conditions. HeLa cells were grown at either 1, 2, 3, 4 and 6mg/ml of glucose. 
Western blot analysis was performed with an anti- V1A1 or anti- V1B1/2 antibody 
primary antibody. Band sizes were consistent for all glucose levels. Two isoforms 
of the A subunit are represented at 116kDa and 70kDa. B1 subunit of the V-
ATPase is located at 56kDa. Protein levels were standardized using tubulin 
protein levels. 
26 
 
0.00 
1.50 
3.00 
4.50 
6.00 
7.50 
9.00 
10.50 
12.00 
13.50 
15.00 
16.50 
1 2 3 4 6 
%
 A
dj
us
te
d 
Vo
lu
m
e 
Glucose Concentration (mg/ml) 
V1A1 Protein Levels 
Figure 9.V-ATPase protein levels. Quantification of the V1A1 Western 
Blot products indicates that the V-ATPase protein synthesis remains 
constant for all glucose concentrations. 
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Inhibiting early glycolysis inhibits influenza viral infection  
 a) Glycolysis inhibition of hexokinase with 2-DG and 3-BrPa lowered influenza 
viral infection.  Glycolysis inhibition with LND led to an increase in influenza 
infection:  Glucose metabolism was previously shown to affect the pumps 
assembly/disassembly (Parra & Kane 1998). ATP hydrolysis is needed to maintain pump 
assembly (Parra & Kane 1998). The pump disassembly was also attributed to a reduction 
in ATP levels (Para and Kane 1998). In this approach, I determined the effect of 
glycolytic inhibition on influenza infection.  MDCK cells were treated for 24 hr with 2-
DG, 3-BrPa and LND inhibitors of hexokinase, the first enzyme of the glycolytic 
pathway. 2-DG is an analogue of glucose and binds to hexokinase (thus inhibiting 
glucose phosphorylation by hexokinase) (Rui-hua Xu et al. 2005). 3-BrPa is an alkylating 
agent that inhibits hexokinase. LND is a molecule that inhibits glycolysis through 
inactivation of hexokinase. Immunostaining was conducted using an anti-HA antibody 
(Figure 10) and the percentage of infected cells was determined for each inhibitor 
treatment at their relative concentrations (Figure 11). The observed results indicate that 2-
DG and 3-BrPa are effective inhibitors of influenza viral infection.  Infection was 
lowered by 92.8% which was obtained by calculating the percent decrease of infected 
cells at 0mM and 5mM of 2-DG. Overall, a significant reduction in infected cells (P-
value = 0.012) was observed when comparing the control treatment with 5mM of 2-DG.  
Additional, infection was reduced by 81.8% with 3-BrPa when comparing 0 µM and 
600µM of 3-BrPa (P-value = 0.035) (Figure 11 A, B). It is also important to note that 
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viral infection was not fully inhibited at 600µM of 3-BrPa. Unexpectedly, there was an 
increase in infection with LND treatment as I increased levels of the inhibitor (P-value = 
0.05) (Figure 11 C).  The obtained results were observed because LND reportedly 
enhanced glycolysis in normal cells, only causing a decrease in glycolysis in cancer cells 
(Floridi et al. 1981).  
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Figure 10. Confocal imaging of glycolytic pathway inhibition on influenza viral infection. MDCK cells were treated 
for 24hr with the glycolytic inhibitors 2-DG (0, 0.25, 2, 5mM), 3-BrPa (0, 30, 300, 600µM) and LND (0, 6, 62.5, 200µM,) 
and subsequently infected with influenza H1N1 for 24hr. Blue stains represent the DNA of a single cell (DAPI) and red 
staining (CY3) represent anti-HA antibody staining within infected cells. Arrows indicate infected cells after treatment 
with glycolytic inhibitors. Confocal imaging was performed at 400x at a scale of 20 µM. 
 
 
 
 
30 
0.0% 0.0% 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
6.0 
7.0 
0 0.25 2 5 
In
fe
ct
ed
 c
el
ls
 (%
) 
2-DG (mM) 
2-DG Treatment  A 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
0 30 300 600 
In
fe
ct
ed
 c
el
ls
 (%
) 
3-BrPa (µM) 
3-BrPa Treatment  B 
0.0 
2.0 
4.0 
6.0 
8.0 
10.0 
12.0 
14.0 
16.0 
18.0 
20.0 
0 6 62.5 200 
In
fe
ct
ed
 c
el
ls
 (%
) 
LND (µM) 
LND Treatment  C 
 
 
 
 
 
 
 
 
Figure 11. Percentage of infected cells after glycolytic inhibition. A, B, C, MDCK cells were treated for 24hr with the  
glycolytic inhibitors  2-DG (0, 0.25, 2, 5mM), 3-BrPa (0, 30, 300, 600µM) and LND (0, 6, 62.5, 200µM,) and subsequently 
infected with influenza H1N1 for 24hr. Cells were immunostained for determination of the percentage of infected cells. 
Number of infected cells for each concentration when compared to the control treatment had a P-value ≤ 0.05. 
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 b) Addition of extracellular ATP restored influenza viral infection: A further 
important approach that was conducted was to bypass glucose metabolism through 
addition of extracellular ATP and determine the subsequent influenza infection of cells. 
To accomplish this approach, 2-DG was used since my previous results indicate that 
infection was completely inhibited, compared to 3-BrPa, at the highest concentration 
used. Cells were first treated with the glycolytic inhibitor 2-DG (5mM) for 24hr. 
Influenza infection and ATP addition (50, 100µM) were conducted simultaneously.    
Immunostaining was performed with an anti-influenza protein (HA) antibody to detect 
infected cells. Viral infection remained unchanged at (-) ATP (Figure 12 A). 20.8% of 
infected cells was observed at 50µM ATP compared to (-) ATP with P-value = 0.004. A 
P-value of 0.006 was obtained when comparing (-) ATP to 100µM ATP treatment.  The 
percentage of infected cells was relatively equal at 50µM and 100µM of ATP, and 
remained at 0% when ATP was not added (Figure 13).  
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Figure 12. Effect of the addition of extracellular ATP. A, B, C, MDCK cells were treated for 24hr with the glycolytic 
inhibitor 2-DG (5mM) and subsequently infected with influenza A H1N1 for 24hr. ATP (50µM, 100µm) was added 
simultaneously. The control group was not treated with ATP after glycolytic inhibition. Arrows indicate HA protein of 
infected cells (CY3 red staining). DNA is stained in blue (DAPI). Confocal imaging was performed at 400x at a scale of 20 
µM. 
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Figure 13. Percentage of infected cells after addition of extracellular 
ATP.  Infection was restored 24hr post treatment with ATP with a P-value ≤ 
0.05 comparing both ATP treatment group to the control (-) ATP. Percentage 
of infected cells were relatively equal at 50µM and 100µM of ATP (50µM = 
20.8% and 100µM= 20.4%). (-)ATP n= 0, 50µM ATP n= 35, 100 µM ATP 
n= 82. Note: Percentages were determined relative to the total number of 
cells per confocal image. Note: Percentages were determined relative to the 
total number of cells per confocal image.  
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c) Inhibition of the pentose phosphate pathway lowered influenza infection: Cells were 
treated with 6-AN, an inhibitor of glucose-6-phosphate dehydrogenase, one of the rate 
limiting enzymes of the phosphate pentose pathway. This approach was conducted to 
determine alternative pathways the pumps may utilize to be active and initiate further 
infection.  One potential pathway is the pentose phosphate pathway, which can generate 
intermediates of the glycolytic pathway such as fructose 6- phosphate and glyceraldehyde 
3- phosphate depending on the cell need for energy. Both glycolytic intermediates can 
enter glycolysis and generate additional ATP that the V-ATPase pump can utilize and 
become active. This approach was conducted through immunostaining of MDCK cells to 
determine the percentage of infected cells (Figure 14) by confocal imaging. Inhibition of 
the pentose phosphate pathway lowered influenza viral replication by 100% at 250µM of 
6-AN (Figure 14) when compared to the control, untreated cells (P-value = 0.018).   
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Figure 14. Percentage of infected cells after inhibition of the pentose 
phosphate pathway. Cells treated with the inhibitor of the pentose 
phosphate pathway 6-AN (0, 30, 140, 250µM) showed a decrease in 
infection when 6-AN concentration was increased. 0 µM n= 10, 30 µM n= 
0, 140 µM n= 0 and 250 µM = 0. 
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CHAPTER IV 
DISCUSSION 
 Influenza infection still remains a major public health concern. Most antiviral 
drugs target viral glycoproteins; thus, it is important to identify alternative ways to 
control influenza viral infection/replication by not only targeting viral particles but also 
by targeting the host cellular processes that the virus may utilize to induce infection. In 
this study, I targeted the activity of the V-ATPase proton pumps, which regulate the pH 
of intracellular compartments, in order to control influenza infection/replication.  
 In this report I demonstrated that regulating the V-ATPase pump activity via 
glucose metabolism can be a useful approach in controlling and inhibiting influenza 
infection in mammalian cells. As previously mentioned, the V-ATPase activity can be 
regulated through glucose depletion (Kane 2006) leading to disassembly of the V1 and 
V0 domains. Additionally, in yeast cells it was shown that the pump’s assembly was 
modulated by the relative concentration of extracellular glucose (Para and Kane 1998). 
Comparing low (1mg/ml) and high (6mg/ml) extracellular glucose conditions in 
mammalians cells I  provided additional evidence for a higher activity of the V-ATPase 
pumps at high glucose concentration (Figure 5 B, D), which is consistent with the fact 
that the pumps require ATP hydrolysis to be active. Thus, when more glucose molecules 
are metabolized to generate ATP, the pump’s assembly is maintained or increased. 
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 The higher HA intensity that was observed through visualization of HA staining 
within infected cells (CY3 red stain) at 4 and 6mg/ml glucose suggests that more glucose 
was available to initiate an increase in V-ATPase pump assembly/activity. The increase 
assembly/activity of the pump then led to an increase in virally infected cells (Figure 7).   
 Western blot analysis confirmed that the increased pump localization was not due 
to increased pump subunit synthesis. These results indicate that while higher glucose 
levels lead to an increased assembly of the pumps, the relative protein synthesis of the V-
ATPase pumps is not associated with higher amount of glucose concentrations (Figure 8, 
9). 
 To find an inhibitor of the V-ATPase activity that would inhibit viral infection, I 
focused on the glycolytic pathway. Glycolysis is the process by which glucose 
metabolism occurs to generate a net gain of two ATP, two NADH+ and two molecules of 
pyruvate (Pelicano et al 2006). I analyzed glycolytic inhibition of the hexokinase enzyme 
with 2-DG, 3-BrPa and LND.  Hexokinase is one of the key enzymes of the glycolytic 
pathway. Hexokinase specifically phosphorylates glucose molecule to create glucose-6-
phosphate (G-6P). This activity traps G-6P in the cells and serves as the starting point for 
glucose to enter glycolysis (Peliciano et al. 2006). Thus, by inhibiting hexokinase I 
prevented the initial metabolism of glucose.  2-DG is an analogue of glucose that is 
capable of binding to hexokinase (thus inhibiting glucose phosphorylation by hexokinase) 
(Rui-hua Xu et al. 2005). 3-BrPa is an alkylating agent that inhibits hexokinase. LND is a 
molecule that inhibits glycolysis through inactivation of hexokinase. Additionally, both 
3-BrPa and LND can affect oxidative phosphorylation (Hulleman et al. 2009). I showed 
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that inhibition of the glycolytic pathway for 24hr with 2-DG and 3-BrPa specifically 
reduced influenza infection compared to cells that were not treated with the inhibitors. 
Thus, the intracellular ATP level was lowered, leading to a decrease in the pump activity 
which is also consistent with the pumps needing energy to properly function and help 
induce infection.  A 92.8% decrease in infection was observed with the 5mM 2-DG 
treatment and a reduction of 81.8% with the 600µM 3-BrPa treatment when compared to 
the control group. It is important to note that infection was not completely inhibited at 
600 µM 3-BrPa. Higher 3-BrPa concentrations may be required for complete inhibition 
of influenza infection. While infection was inhibited with 2-DG and 3-BrPa, inhibition of 
hexokinase with LND significantly increased influenza infection in MDCK cells. The 
relevant results were observed because LND reportedly enhances glycolysis in normal 
cells, only causing a decrease in glycolysis in cancer cells (Floridi et al. 1981). Additional 
information about this preference in activity by LND is scarce. However, this selection in 
activity may be due to the mitochondrially bound hexokinase which is usually absent in 
normal cells (Floridi et al. 1981). 
 ATP is considered to activate the V-ATPase pumps by binding to its catalytic site 
on the A and B subunits of the pump. In the present study, I bypassed glucose 
metabolism through the addition of extracellular ATP after inhibition of glycolysis. 
Addition of extracellular ATP after glycolytic inhibition with 2-DG (5mM) restored 
influenza infection in mammalian culture cells, presumably through reassembly of the V1 
and V0 domains. This suggests that glycolysis is not actually required to take place in 
order to activate the pump. With the results obtained in this study, the presence of ATP 
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may be considered the principal activator of the pumps, and not necessarily the 
interaction of glycolytic enzymes with the V-ATPase pump. 
 Another major approach of my study was to identify an alternative pathway the 
virus may utilize to induce infection.  I inhibited glucose 6-phosphate dehydrogenase, a 
rate limiting enzyme of the pentose phosphate pathway, using 6-AN. The pentose 
phosphate pathway uses sugar to synthesize ribose 5-phosphate in nucleotides or 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) production (Delvin M.T 
2011). This pathway provides a mean of converting ribose 5-phosphate to form 
intermediates of the glycolytic pathway such as fructose 6-phosphate (F6P) and 
glyceraldehydes 3-phosphate (G3P). Both F6P and G3P can enter glycolysis for 
additional ATP synthesis. I found that inhibiting the pentose phosphate pathway caused a 
decrease in influenza viral infection. These findings suggest that generation of additional 
ATP through the pentose phosphate pathway may be an alternative way the pumps may 
utilize to be active when hexokinase, the first enzyme of glycolysis, is inhibited. Thus, 6-
AN can lead to ATP depletion by also interfering with glucose metabolism through 
inhibiting the production of intermediates of the glycolytic pathway. Since the rate 
limiting enzyme of the pentose phosphate was inhibited, not only intermediates of the 
glycolytic pathway but also NADPH production were inhibited. Thus, it may be 
suggested that NADPH is also necessary for viral infection. Further studies will need to 
be conducted to determine if NADPH has a direct effect on V-ATPase activity or directly 
affects viral infection. A model of V-ATPase pump activity and influenza infection is 
presented in Figure 15. 
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Figure 15. Schematic representation of glucose metabolism on V-ATPase activation and influenza viral infection. 
ATP activates the V-ATPase pump by binding to its catalytic site, and protons are transported against the gradient into 
the vesicle.  The acidic environment of the vesicle initiates activation of the M2 ion channel leading to proton transport 
into the viron and subsequent release of viral genome into the cytosol. (Modified from Lu M. , Sautin Y. et al. 2004). 
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